Anti-PD-L1 monoclonal antibodies are usually used in cancer immunotherapy, but aPD-L1 usually has problems such as poor diffusion, low tumor penetration ability, and immune-related adverse reactions [40]. This evidence concerns the gene CD274 and neoplasm.